Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor formulated as a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the impact of hepatic impairment on its pharmacokinetics and protection to address regulatory demands. Inhibition of galectin-3 with GB1211 was not linked to any treatment method- or dose-linked https://johnv099grb1.wizzardsblog.com/profile